The hyperplasia-to-carcinoma sequence in the breast: Immunohistochemical-histologic correlations

Applied Immunohistochemistry and Molecular Morphology

Volumn 8, Issue 2, 2000, Pages 98-103

  Strickland, Leah B ^a   Dawson, Peter J ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Atypical hyperplasia; Breast cancer; Carcinoma in situ; Ductal carcinoma; Immunohistochemistry c erbB 2; P53

Indexed keywords

CYCLIN D1; PROTEIN P53; TUMOR MARKER;

ARTICLE; BREAST CANCER; BREAST CARCINOMA; BREAST DISEASE; BREAST HYPERPLASIA; CARCINOMA IN SITU; CLINICAL ARTICLE; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE C ERB; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBODIES; ANTIGENS, NEOPLASM; BREAST; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CYCLIN D1; FEMALE; GLYCOPROTEINS; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033856308     PISSN: 10623345     EISSN: None     Source Type: Journal    
DOI: 10.1097/00022744-200006000-00003     Document Type: Article

References (32)

1. Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast: a long-term follow up study. Cancer 1985;55:2698-708.
2. Dupont WD, Page DL. Relative risk of breast cancer varies with time since diagnosis of atypical hyperplasia. Hum Pathol 1989;20: 723-5.
3. Zukerberg LR, Yang W-I, Gadd M, et al. Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene. Mod Pathol 1995;8:560-7.
4. Oyama T, Kashiwabara K, Yoshimoto K, Arnold A, Koerner F. Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast Cancer Res 1998;58:2875-80.
5. Alle KM, Henshall SM, Field AS, Sutherland RL. Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. Clin Cancer Res 1998;4:847-54.
6. Inaji H, Koyama H, Motomura K, Noguchi S. Differential distribution of erbB-2 and pS2 proteins in ductal carcinoma in situ of the breast Breast Cancer Res Treat 1996;37:89-92.
7. Coene ED, Schelfhout V, Winkler RA, et al. Amplification units and translocation at chromosome 17q and c-erbB-2 overexpression in the pathogenesis of breast cancer. Virchows Arch 1997;430: 365-72.
8. Porter PL, Garcia R, Moe R, Corwin DJ, Gown AM. C-erbB-2 oncogene protein in in situ and invasive lobular breast neoplasia. Cancer 1991;68:331-4.
9. Allred DC, Clark GM, Molina R, et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 1992;23:974-9.
10. Barnes DM, Bartkova J, Camplejohn RS, Gullick WJ, Smith PJ, Millis RR. Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance? Eur J Cancer 1992;28:644-8.
11. Gusterson BA, Machin LG, Gullick WJ, et al. Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer. Intl J Cancer 1988;42:842-5.
12. Rudas M, Neumayer R, Gnant MFX, Mittelböck M, Jakesz R, Reiner A. p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. Eur J Cancer 1997;33:39-44.
13. Schmitt FC, Leal C, Lopes C. p53 protein expression and nuclear DNA content in breast intraductal proliferations. J Pathol 1995; 176:233-41.
14. Ohuchi N, Page DL, Merino MJ, Viglione MJ, Kufe DW, Schlom J. Expression of tumor-associated antigen (DF3) in atypical hyperplasias and in situ carcinomas of the human breast. J Natl Cancer Inst 1987;79:109-17.
15. Eriksson ET, Schimmelpenning H, Aspenblad U, Zetterberg A, Auer GU. Immunohistochemical expression of the mutant p53 protein and nuclear DNA content during the transition from benign to malignant breast disease. Hum Pathol 1994;25:1228-33.
16. Done SJ, Arneson NCR, Özçelik H, Redston M, Andrulis IL. p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias. Cancer Res 1998;58:785-9.
17. Chitemerere M, Andersen TI, Holm R, Karlsen F, Børresen A-L, Nesland JM. TP53 alterations in atypical ductal hyperplasia and ductal carcinoma in situ of the breast. Breast Cancer Res Treat 1996;41:103-9.
18. Rajan PB, Scott DJ, Perry RH, Griffith CDM. p53 protein expression in ductal carcinoma in situ (DCIS) of the breast. Breast Cancer Res Treat 1997;42:283-90.
19. Millikan R, Hulka B, Thor A, et al. p53 mutations in benign breast tissue. J Clin Oncol 1995;13:2293-300.
20. Seth A, Palli D, Mariano JM, et al. p53 gene mutations in women with breast cancer and a previous history of benign breast disease. Eur J Cancer 1994;30A:808-12.
21. Frierson HF, Gaffey MJ, Zukerberg LR, Arnold A, Williams ME. Immunohistochemical detection and gene amplification of cyclin D1 in mammary infiltrating ductal carcinoma. Mod Pathol 1996; 9:725-30.
22. Maguire HC, Hellman ME, Greene MI, Yeh I. Expression of c-erbB-2 in in situ and in adjacent invasive ductal adenocarcinoma of the female breast. Pathobiology 1992;60:117-21.
23. Page DL, Rogers LW. Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Hum Pathol 1992;23:1095-7.
24. Dawson PJ, Baekey PA, Clark RA. Mechanisms of multifocal breast cancer: an immunohistochemical study. Hum Pathol 1995; 26:965-9.
25. Rosenberg CL, de las Morenas A, Huang K, Cupples LA, Faller DV, Larson PS. Detection of monoclonal microsatellite alterations in atypical breast hyperplasia. J Clin Invest 1996;98:1095-100.
26. Noguchi S, Motomura K, Inaji H, Imaoka S, Koyama H. Clonal analysis of predominantly intraductal carcinoma and precancerous lesions of the breast by means of polymerase chain reaction. Cancer Res 1994;54:1849-53.
27. Lakhani SR, Collins N, Stratton MR, Sloane JP. Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. J Clin Pathol 1995;48: 611-5.
28. O'Connell P, Pekkel V, Fuqua SAW, Osborne CK, Clark GM, Allred DC. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 1998;90:697-703.
29. Deng G, Lu Y, Zlotnikov G, Thor AD, Smith HS. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science 1996;274:2057-9.
30. Iravani S, Mora L, Miller FR, Dawson PJ. Altered expression of c-erbB-2, DF3, B72.3, p53 and Ki-67 with progression and differentiation to two distinct histologic types of invasive carcinoma in the MCF10AT human xenograft model of proliferative breast disease. Int J Oncol 1998;12:369-75.
31. Iglehart JD, Kerns B-J, Huper G, Marks JR. Maintenance of DNA content and erbE-2 alterations in intraductal and invasive phases of mammary cancer. Breast Cancer Res Treat 1995;34:253-63.
32. Davidoff AM, Kerns B-J, Iglehart JD, Marks JR. Maintenance of p53 alterations throughout breast cancer progression. Cancer Res 1991;51:2605-10.